NovoCure Stock Still Up Ahead of Cancer Trial Data
NovoCure shares closed at $17.96 Friday, up 0.3%, and slipped to $17.71 after hours ahead of the Memorial Day market closure. The stock remains about 50% above its April 29 close, after the company raised its 2026 revenue forecast and reported Q1 revenue of $174.1 million. NovoCure had 4,791 active patients at March’s end, including 83 on its new pancreatic cancer device.